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Summary and future perspectives
Summary
The overall premise of this thesis is that biomarker-based approaches 
can be utilized to tailor pharmacological therapy in diabetic kidney dis-
ease. Diabetic kidney disease (DKD) is a heterogeneous disease with 
a complex underlying pathophysiology. Prior studies have shown that 
patients with DKD show a large variability in response to drug ther-
apy. Analyses from completed large-scale clinical trials revealed that this 
individual drug response variability explains in part why several inter-
ventions tested in these large trials did not result in additional renal 
or cardiovascular protection.[1–3] These findings emphasize the need 
to develop personalized strategies that take into account individual re-
sponse variability in order to allocate drug treatment to individuals who 
will more likely benefit most from it. It has recently been shown that 
it may be feasible to use short-term changes in biomarkers to enrich 
clinical trials; the success of this still needs to be evaluated.[4] More re-
search is also needed to identify biomarkers that can predict long-term 
efficacy of different drugs in patients with DKD. 
The aim of this thesis was to explore whether (changes in) routinely 
measured biomarkers before drug exposure or during a short-term pe-
riod of drug treatment predict individual drug response on long-term 
renal outcomes. Chapter 2 and 3 evaluated the use of single predictive 
and dynamic biomarkers to predict drug effects on long-term outcomes. 
In the subsequent chapters, we explored the utility of a previously devel-
oped model which integrates short-term effects on multiple biomarkers 
to predict the long-term impact of different novel pharmacological in-
terventions on renal disease progression.
In Chapter 2, a post hoc analysis was performed among 5081 pa-
tients with type 2 diabetes mellitus to investigate whether NT-proBNP, a 
marker of vascular wall stress and fluid overload, can predict the effects 
of additional therapy with the direct renin inhibitor aliskiren on cardio-
renal endpoints. The primary results of the trial showed that on a pop-
ulation level, aliskiren did not confer renal or cardiovascular protection. 
The current study showed that the relative risks for cardiovascular and 
renal events achieved with additional aliskiren therapy were modified 
by baseline NT-proBNP levels. At higher NT-proBNP levels, aliskiren 
compared to placebo increased the risk of the cardiorenal endpoint, 
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while in the lower NT-proBNP tertile, treatment with aliskiren tended 
to reduce cardiorenal risk. Effects of aliskiren compared to placebo on 
safety outcomes (hyperkalemia and hospitalization for acute kidney 
injury) were independent of NT-proBNP. Earlier studies showed that 
extracellular volume restriction, by means of moderating dietary so-
dium intake or concomitant diuretic treatment improved the efficacy of 
RAAS blockade to decrease cardiorenal risk. The results of the present 
study suggest that NT-proBNP can help to identify individuals who 
may not respond to dual RAAS inhibition with aliskiren and who may 
benefit from diuretic treatment or dietary sodium lowering.
Chapter 3 presents a study in 471 patients with proteinuria who 
participated in the PLANET I and II (Renal effects of Rosuvasta-
tin and Atorvastatin in Patients Who Have Progressive Renal Dis-
ease) trials that examined effects of atorvastatin and rosuvastatin on 
proteinuria and renal function. The PLANET trials showed that the 
proteinuria response to rosuvastatin and atorvastatin differ despite a 
similar response in cholesterol at a population level. In this post hoc 
analysis we found that proteinuria and cholesterol response from base-
line to 14 weeks were not only variable between the statins, but also 
highly variable between patients for both statins. In addition to this 
between-patient variability, we observed that a reduction in proteinuria 
was not accompanied by a cholesterol reduction in a substantial num-
ber of patients. The individual responses in proteinuria and cholesterol 
predicted eGFR decline during the subsequent 9 months of follow-up: 
a response in both proteinuria and cholesterol was associated with a 
stable renal function, whereas non-responders in both proteinuria and 
total cholesterol showed the fastest rate of eGFR decline, independent 
of the type of statin. These findings suggest that changes in both pro-
teinuria and cholesterol should be individually monitored to identify 
who will benefit from statin therapy. 
In Chapter 3, we demonstrated that statins exert multiple effects that 
do not run in parallel within an individual. These results extend on 
those from earlier studies, in which the same phenomenon was observed 
for angiotensin receptor blockers (ARBs).[5–7] Importantly, changes 
in separate biomarkers were independently associated with long-term 
renoprotection, implying that multiple short-term drug effects should 
be taken into account to adequately predict long-term drug response. 
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It has been shown that the PRE score, by integrating changes in risk 
markers after a short period of treatment, can be utilized to predict 
long-term drug response. Several existing risk scores were developed 
and validated to predict the risk for renal disease progression based 
on multiple baseline features. Up to now, it has not been determined 
whether these scores can also be used to predict response to drug 
therapy. In Chapter 4, we therefore compared two existing risk scores 
with the PRE score in their ability to predict long-term renal effects of 
ARB therapy in patients with type 2 diabetes and kidney disease. While 
all included scores showed a generally good performance for risk pre-
diction at baseline, the PRE score provided more accurate predictions 
of long-term ARB effects on renal outcomes than the two existing risk 
scores. This implies that algorithms developed to predict absolute risk – 
which do not necessarily include biomarkers that reflect short-term 
drug effects – may not adequately predict relative benefit conferred 
by drug therapy. Alternatively, a multiple response score such as the 
PRE score may assist in better long-term drug efficacy prediction and 
identify patients who are most likely to benefit from pharmacological 
intervention. In the last part of this thesis, we assessed the utility of 
the PRE score for other drug classes that are currently used to reduce 
cardiovascular and/or renal risk in patients with type 2 diabetes. 
In Chapter 5, we performed a secondary analysis on EXSCEL (Ex-
enatide Study of Cardiovascular Event Lowering), a placebo-controlled 
trial investigating the cardiovascular safety of the glucagon-like pep-
tide-1 analogue (GLP-1 RA) exenatide in a broad range of patients 
with type 2 diabetes with or without atherosclerotic cardiovascular dis-
ease. Exenatide reduced glycated haemoglobin levels after 6 months 
treatment, but also significantly lowered several other cardio-renal risk 
markers, including systolic blood pressure and progression to micro- of 
macroalbuminuria. By integration of these short-term effects using the 
PRE score we calculated a substantial relative risk reduction in renal 
events which was of similar magnitude to the relative risk reduction ob-
served in the trial. These results imply that the utility of the PRE score 
extends to GLP-1 RAs, suggesting that this algorithm may be used as 
a tool to predict treatment response for this class of drugs. Overall, the 
results of this study support further clinical trials to prospectively assess 
the renal efficacy of exenatide. 
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In Chapter 6 we assessed whether the PRE score could predict the 
long-term effects of the sodium glucose co-transporter 2 (SGLT2) in-
hibitor dapagliflozin on renal and heart failure outcomes. The short-
term effects of dapagliflozin on multiple biomarkers were established 
in patients with type 2 diabetes and chronic kidney disease who partic-
ipated in a Phase 3 program of dapagliflozin clinical trials. Integration 
of the observed short-term drug effects by the PRE score indicated 
that treatment with dapagliflozin would confer considerable improve-
ments in kidney and heart failure outcomes in these patients. The pre-
dicted risk reductions on dapagliflozin were very similar to the long-
term effects of SGLT2 inhibition as observed in recent cardiovascular 
outcome trials in patients with type 2 diabetes at high cardiovascular 
risk. A large ongoing dapagliflozin outcome trial (DAPA-CKD; NCT 
03036150) will provide a more definitive answer as to whether the pre-
dicted effects of dapagliflozin in patients with chronic kidney disease 
are accurate and will thus validate or refute these predictions.
Future perspectives
In this thesis, we investigated strategies based on predictive and dynamic 
biomarkers to tailor pharmacological therapy in patients with DKD. Uti-
lizing the PRE score, which translates short-term changes in biomarkers 
into a predicted long-term drug response, appears to be a promising 
strategy to personalize drug therapy. The PRE score may be used in clin-
ical practice to monitor individual drug response and guide treatment 
decisions. Additionally, it may be applied in future clinical trials to es-
timate treatment effects on renal outcomes during early stages of drug 
development that can support the decision as to whether the drug should 
be tested in phase III clinical trials. Finally, the PRE score can aid en-
richment of clinical trials. During an enrichment phase, patients can be 
selected based on estimated drug effects on multiple risk markers calcu-
lated by the PRE score. This approach enables the inclusion of patients 
who are likely to respond to the drug, as well as the exclusion of patients 
who are prone to experience harmful effects of the new intervention. 
What is needed to integrate the PRE score in future practice? The 
PRE score adequately predicts long-term drug response on a population 
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level for several drug classes. Prospective, pre-specified trials in which 
the PRE score is used to monitor and adjust pharmacological therapy 
in clinical practice are required to test whether the PRE score can also 
be used to improve patient outcomes on an individual patient level. 
In such a study patients would be randomly assigned to a PRE score 
guided treatment regimen and care as usual and be followed for long-
term clinical outcomes. Treatment recommendations would be given in 
both treatment arms according to clinical practice guidelines but the 
PRE score guided treatment arm will be informed by an individuals 
predicted drug response based on changes in multiple biomarkers. The 
intricacies of this type of study would have to be well thought through 
before trial implementation, e.g. the selection of clinically relevant end-
points with sufficient level of evidence and whether to randomize par-
ticipants at the practice or patient level. Such prospective studies will 
provide evidence necessary for the PRE score to be used for optimally 
informing treatment decisions. 
Implementation of biomarker-based response scores such as the PRE 
score is only one aspect of personalized medicine. Personalized treat-
ment encompasses many other facets such as advancing treatment ad-
herence and stimulate shared decision making. Regardless of the dif-
ferent aspects of personalized medicine, its implementation requires a 
multi-faceted approach involving many stakeholders. Different stake-
holders have different priorities and focus areas for personalized med-
icine. For example, regulatory agencies would have to develop models 
to assess efficacy and safety, and pharmaceutical companies would have 
to market drugs for specifically targeted patient populations. Health-
care providers would focus on the development of new guidelines and 
implementation of biomarker based approaches in clinical practice and 
clinicians would require education in the topic of personalized medicine, 
e.g. on which diagnostics and drugs to test and prescribe for specific 
patient populations. Importantly, the implementation of personalized 
treatment in DKD would require close involvement of patients since 
they are the most important end-users of healthcare. 
This thesis was conducted under the umbrella of the BEAt-DKD 
project. One of the important aims of BEAt-DKD consortium is to 
promote implementation of personalized medicine. BEAt-DKD works 
towards this by supporting stakeholder engagement and collaboration. 
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Discussions with multiple stakeholders are ongoing to identify and 
eventually align different interests, to overcome obstacles, and to strate-
gize solutions to move personalized medicine forward in DKD. For in-
stance, patients and patient organizations support the implementation 
of a drug response score such as the PRE score since it may provide ac-
cess to individualized therapy that improves quality of life. Health care 
providers would be generally willing to use the PRE score in clinical 
practice as it would support individualized, evidence based treatment 
decisions. However, models of therapy response must be translated in 
reliable and efficient applications for clinical practice. Regulatory agen-
cies and health policy makers require prospective clinical trial evidence 
demonstrating that implementation of the PRE score results in addi-
tional benefit as compared to existing treatment decision tools in terms 
of gain in healthy patient years. These ongoing joint efforts to reach a 
consensus on the implementation of personalized methodologies such 
as the PRE score are essential to translate personalized treatment in 
patients with DKD from research to clinical practice.
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